Kymera Therapeutics Inc annual earnings per share (EPS) for fiscal TTM was $-3.30, an increase of 10.6% from $-3.69 in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EPS (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-3.30 | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-1.02 | $-0.93 | $-0.48 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EPS (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (EPS) | $-0.62 | $-0.71 | $-1.03 | $-0.94 | $-0.95 | $-0.82 | $-0.88 | $-0.82 | $-0.58 |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More KYMR metrics: Revenue · Gross Profit · Operating Income · Net Income · EBITDA · Free Cash Flow · Shares Outstanding
All KYMR financial statements → Interactive KYMR charts →
About TickerBase · Data methodology & sources · Privacy · Terms